Swiss medical weekly最新文献

{"title":"First reported human Castellaniella defragrans bacteraemia: a case report.","authors":"Morgane Nédellec, Titouan Cerruti, Damien Jacot, Gilbert Greub, Malik Benmachiche","doi":"10.57187/5401","DOIUrl":"https://doi.org/10.57187/5401","url":null,"abstract":"<p><p>Castellaniella defragrans is an environmental Gram-negative, non-fermenting β-proteobacterium that is not known as a human pathogen. Here, we report the first documented case of C. defragrans bacteraemia in an 82-year-old man with monoclonal B-cell lymphocytosis, subsequently diagnosed with chronic lymphocytic leukaemia, who presented with fever, confusion and clinical signs of sepsis. Blood cultures showed sustained growth of C. defragrans for 7 days. Imaging revealed pulmonary consolidations and mediastinal infiltration suggestive of mediastinitis. Further investigations did not identify a clear additional infectious focus. In addition, an immunological evaluation revealed severe cellular and humoral immunosuppression. Antimicrobial therapy with high-dose meropenem led to bacteraemia clearance and progressive clinical improvement. Treatment was completed with oral sulfamethoxazole-trimethoprim for a total of five weeks. This case highlights the potential of environmental microorganisms to cause severe infections in immunocompromised hosts.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5401"},"PeriodicalIF":1.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of reporting notifiable infectious diseases - the Swiss reporting system.","authors":"Michelle Raess, Annora Celant, Mirjam Mäusezahl","doi":"10.57187/5508","DOIUrl":"10.57187/5508","url":null,"abstract":"<p><p>The structured processes of clinical medicine and epidemiology are closely aligned, with disease reporting serving as the critical interface between individual patient care and population-level public health action. In Switzerland, mandatory reporting of communicable diseases forms the backbone of national infectious disease surveillance and relies on coordinated contributions from clinicians and laboratories. The Swiss reporting system is regulated by an ordinance that defines notifiable diseases, reporting criteria and strict timelines. It encompasses severe diseases, outbreak-prone infections, and endemic or vaccine-preventable conditions, and is continuously updated to reflect evolving epidemiological threats. Accurate case classification depends on the integration of both clinical and laboratory data; incomplete reporting compromises data quality and can lead to misclassification and biased epidemiological conclusions. In recent years, reporting compliance - particularly for clinical notifications - has declined significantly. This deterioration in data completeness limits the ability to detect outbreaks, assess trends and implement timely and targeted public health interventions. Contributing factors include administrative burden, limited awareness of reporting obligations and insufficient understanding of the public health value of reporting. High-quality reporting is essential for multiple public health functions: enabling rapid containment measures such as contact tracing and isolation, supporting outbreak detection through statistical surveillance and genomic analysis, informing national health policies and vaccination strategies, and facilitating research. Surveillance data are routinely analysed and disseminated via national dashboards and international collaborations. In conclusion, although reporting imposes additional demands on clinicians, it remains a fundamental component of effective public health practice. Strengthening reporting compliance and data quality is critical to ensuring timely interventions, reducing disease burden and maintaining resilient health systems. Improved digital solutions may alleviate reporting burdens; however, sustained clinician engagement and recognition of their role in public health are indispensable.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5508"},"PeriodicalIF":1.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-hospital cardiac arrest management in the Swiss canton of Valais: a retrospective study on first responders' response and automated external defibrillator efficacy.","authors":"Athiththan Kanthasamy, Patrizio Pascale, Grégoire Girod","doi":"10.57187/4761","DOIUrl":"https://doi.org/10.57187/4761","url":null,"abstract":"<p><strong>Study aims: </strong>Cardiac arrest is a condition with a high mortality rate, with most cases occurring outside hospital. First responders (defined as public responders in our study) play an increasingly important role in management through the early initiation of cardiopulmonary resuscitation and defibrillation. Several studies have shown that the involvement of public responders can result in faster initiation of resuscitation and increased survival. This study evaluated the management of out-of-hospital cardiac arrest by public responders and the effectiveness of the FRED-PA1 automated external defibrillator (AED) available in the canton of Valais, Switzerland.</p><p><strong>Methods: </strong>This was a retrospective study including consecutive cases of out-of-hospital cardiac arrest occurring between January 2021 and December 2023 in the canton of Valais. Response times of public responders and emergency medical services (EMS) were evaluated, along with initial rhythms, survival, and the performance and safety of the available AEDs.</p><p><strong>Results: </strong>A total of 107 patients were included in the study. In 68% of cases, a public responder arrived at the scene first, with a significantly shorter interval between emergency call and on-site arrival compared with EMSs (p = 0.019). Ventricular fibrillation was more frequent in the EMS group than the public responders group (35 vs 23%) (non-significant [NS]). Survival on arrival at hospital was 19% in the public responder group and 24% in the EMS group (NS). Survival to hospital discharge was 9.6% in the public responder group and 15% in the EMS group (NS). Concerning the AEDs, the rhythm recognition algorithm was deemed to be effective and consistent with current recommendations.</p><p><strong>Conclusion: </strong>This retrospective study demonstrates the key role played by public responders, who are frequently the first to arrive at the scene of out-of-hospital cardiac arrests. The FRED-PA1 AED algorithm meets the standards in the literature. However, ongoing prospective studies will highlight and optimise the role of public responders in out-of-hospital cardiac arrests.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4761"},"PeriodicalIF":1.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An unusual cause of a necrotic bullous skin lesion: a case report.","authors":"Katharina Knapp, Stephanie Holzer, Marius Schlienger","doi":"10.57187/5215","DOIUrl":"https://doi.org/10.57187/5215","url":null,"abstract":"<p><strong>Background: </strong>Tularaemia is a zoonotic infection uncommon in Switzerland, but its incidence is increasing. Thus, tularaemia should also be considered in returning travellers with compatible exposure history. We report a case of ulceroglandular tularaemia presenting with a necrotic bullous skin lesion.</p><p><strong>Case presentation: </strong>A man in his 30s presented with a necrotic bullous lesion on the right palm, accompanied by ipsilateral axillary and supraclavicular lymphadenopathy. Eleven days prior, during a stay in Canada, he developed an itchy skin lesion and reported direct contact with a hare carcass five days before symptom onset. He initially received antibiotic therapy with a cephalosporin, which did not result in clinical improvement. A swab obtained from the lesion tested positive for Francisella tularensis subsp. tularensis by polymerase chain reaction (PCR), and serology confirmed the result.</p><p><strong>Treatment and outcome: </strong>Antibiotic therapy was initially switched to doxycycline (100 mg twice daily), but discontinued after 6 days because of a sore throat suggestive of oesophageal irritation. Ciprofloxacin (500 mg twice daily) was subsequently administered for 10 days, during which the lesion, lymphadenopathy and general symptoms resolved rapidly. This case highlights the importance of thorough exposure history and the early consideration of tularaemia in patients with necrotic skin lesions and regional lymphadenopathy, particularly when there is no response to standard antibiotic therapy. Early diagnosis allows for appropriate antimicrobial treatment and favourable outcomes.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5215"},"PeriodicalIF":1.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalisations with myocarditis before and during the COVID-19 pandemic - a nationwide cohort study.","authors":"Jérémie Héritier, Rahel Laager, Andreas Schelldorfer, Claudia Gregoriano, Beat Müller, Philipp Schuetz, Alexander Kutz","doi":"10.57187/4794","DOIUrl":"https://doi.org/10.57187/4794","url":null,"abstract":"<p><strong>Aims of the study: </strong>Over the past decade, there has been a steady increase in myocarditis cases, paralleling the expanded availability and use of cardiac magnetic resonance imaging. Although some have speculated that COVID-19 or its vaccines may be contributing to this increase, recent studies have not provided conclusive proof. Therefore, this study aims to analyse the association between COVID-19 and myocarditis in hospitalised patients.</p><p><strong>Methods: </strong>In this nationwide cohort study, the primary outcome was trends in hospitalisations with myocarditis before (years 2012-2019) and during (years 2020-2022) the COVID-19 pandemic. Trends were calculated using linear mixed-effects segmented regression models. Secondary outcomes included in-hospital mortality, intensive care unit admission, length of stay, and 30-day hospital readmission. Results were stratified by sex and age for subgroup analyses.</p><p><strong>Results: </strong>During the pre-pandemic period, 4,304 hospitalisations with myocarditis were recorded, compared with 2,749 during the pandemic. The incidence rate of myocarditis increased from 26.7 cases per 100,000 hospitalisations in 2012 to 73.8 per 100,000 in 2022 (p for trend <0.001). The quarterly slope of incidence rose significantly during the pandemic (slope, 2.008 [95% CI: 2.006 to 2.011]) compared with that during the pre-pandemic period (slope, 1.141 [95% CI: 1.140 to 1.141]). Subgroup analyses showed the steepest increases in young and middle-aged males. Sensitivity analyses based on the Swiss population confirmed this pattern, with a population-adjusted quarterly increase in myocarditis hospitalisations from 1.0 to 2.6 per 100,000 inhabitants between 2012 and 2022 (p for trend <0.001).</p><p><strong>Conclusion: </strong>This nationwide cohort study found a marked increase in the incidence of hospitalisations with myocarditis during the COVID-19 pandemic, suggesting a causal relationship between COVID-19 infection and/or its vaccination and the increased incidence of myocarditis.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4794"},"PeriodicalIF":1.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of anaphylaxis in a Swiss university hospital emergency department: a retrospective observational study assessing adherence to epinephrine administration.","authors":"Élie Smith, Francois-Xavier Ageron, Denis Comte, Fabrice Dami, Christophe Bianchi","doi":"10.57187/5086","DOIUrl":"https://doi.org/10.57187/5086","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Anaphylaxis is a severe and potentially life-threatening allergic reaction, most frequently triggered by food, medication and insect venom. Its diagnosis is challenging due to the absence of pathognomonic signs and instead relies on the sudden onset of multisystem symptoms. Although international guidelines recommend intramuscular (i.m.) epinephrine as the first-line treatment, several studies suggest that it remains underused, with antihistamines and corticosteroids still frequently administered. This highlights a persistent gap between guideline recommendations and real-world clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess use of i.m. epinephrine in patients with anaphylaxis and to identify factors associated with its administration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a single-site, retrospective observational study of all consecutive patients presenting to the emergency department (ED) of a Swiss university hospital who were triaged under the \"allergy\" category between 1 January 2022 and 31 December 2023. Among these patients (n = 915), 277 met the World Allergy Organization (WAO) criteria for anaphylaxis, 553 were identified as non-anaphylactic immediate allergic reactions and 85 were excluded due to missing data or missed triage. For the 915 patients, data on the medical history, vital signs, clinical examination, management and the discharge summary were extracted from the hospital information system for analysis. Cases were classified as anaphylactic or non-anaphylactic immediate allergic reactions, based on the WAO systemic allergic reaction grading system. Treatments received in the ED were then analysed. The primary outcome was the proportion of patients with anaphylaxis who received i.m. epinephrine as first-line treatment. The secondary outcome was the identification of clinical and demographic factors associated with its administration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among patients meeting the WAO criteria for anaphylaxis, only 30.1% received i.m. epinephrine. Antihistamines and/or corticosteroids, despite being regarded as second-line treatments, were administered without epinephrine in 39.4% of cases. The administration of epinephrine was positively associated with older age, respiratory or cardiovascular symptoms, elevated heart rate and reduced systolic blood pressure. In contrast, it was less likely in females and in those presenting anaphylaxis with mucocutaneous symptoms. Gastrointestinal symptoms were not significantly associated with the likelihood of receiving i.m. epinephrine.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Despite clear guideline recommendations, the use of i.m. epinephrine in anaphylaxis remains suboptimal, with frequent reliance on second-line therapies. Female sex was independently associated with underuse, highlighting a potential sex bias. In contrast, haemodynamic instability and respiratory or ear-nose-throat involvement increased the likelihood of app","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5086"},"PeriodicalIF":1.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical inactivity attributable burden of disease on morbidity and mortality across Swiss language regions: a population-based modelling study.","authors":"Lara Güntert, Jan Taeymans, Heiner Baur, Marcus Van Dyck, Nathanael Lutz","doi":"10.57187/5162","DOIUrl":"https://doi.org/10.57187/5162","url":null,"abstract":"&lt;p&gt;&lt;p&gt;  BACKGROUND: Physical inactivity is a major risk factor for noncommunicable diseases, contributing to both substantial morbidity and premature mortality. In Switzerland, the prevalence of physical inactivity varies across language regions. This study aimed to quantify differences across Swiss language regions in the physical inactivity-attributable burden of disease, expressed as Years Lived with Disability (YLD) and Years of Life Lost (YLL) for 2022. The analysis focuses on YLD and YLL attributable to physical inactivity across 15 physical inactivity-associated diseases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study employed the Population Attributable Fraction approach to estimate the proportion of YLD and YLL attributable to physical inactivity in Switzerland. The analysis included individuals aged &gt;20 years and was stratified by disease, age, sex and language region (German-, French- and Italian-speaking). Physical inactivity was defined according to WHO guidelines as not meeting at least 150 minutes of moderate or 75 minutes of vigorous physical activity per week. Prevalence data on physical inactivity were derived from the 2022 Swiss Health Survey. Prevalences were combined with relative risks (RR) of corresponding diseases, identified through a systematic literature search to derive Population Attributable Fractions. Estimates of YLD and YLL for Switzerland for 2022 were derived from the Global Burden of Disease study. YLD and YLL estimates attributable to physical inactivity are presented as rates per 100,000 people aged &gt;20 years. Uncertainty was assessed using parametric bootstrapping.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Overall, the physical inactivity-attributable burden of disease was estimated at 227.08 (95% CI: 214.74-240.08) YLD and 424.23 (95% CI: 383.15-479.23) YLL per 100,000 people aged &gt;20 years. This corresponds to approximately 2% of total DALYs in Switzerland in 2022. Clear regional differences were observed. Estimated physical inactivity-attributable YLD rates were highest in the Italian-speaking region (134.90; 95% CI: 122.04-148.25) followed by the French-speaking region (130.72; 95% CI: 120.78-141.50) and German-speaking region (96.26; 95% CI: 88.81-104.01). Similarly, estimated YLL rates attributable to physical inactivity were highest in the Italian-speaking region (287.74; 95% CI: 245.82-349.99), followed by the French-speaking region (221.56; 95% CI: 192.54-264.55) and German-speaking region (186.67; 95% CI: 162.64-222.27). Disease-specific analysis indicated that depression (93.38; 95% CI: 85.46-101.80) and low back pain (52.01; 95% CI: 45.90-58.47) contributed most to physical inactivity-attributable YLD rates, whereas coronary heart disease (132.12; 95% CI: 115.60-149.55) and Alzheimer's disease and dementia (83.61; 95% CI: 51.90-134.97) were the main contributors to physical inactivity-attributable YLL rates. Women showed consistently higher burden of disease than men, with physical inactivity-attributable YLD ","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5162"},"PeriodicalIF":1.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in prescription patterns of secondary prevention pharmacotherapy in patients with acute myocardial infarction: a 20-year insight from the AMIS Plus registry.","authors":"Lara Berther, Dragana Radovanovic, Marco Roffi, Barbara Stähli, Giovanni Pedrazzini, Hans Rickli, On Behalf Of The Amis Plus Investigators","doi":"10.57187/4681","DOIUrl":"https://doi.org/10.57187/4681","url":null,"abstract":"<p><strong>Aims: </strong>Recent studies have demonstrated sex-related differences in secondary prevention pharmacotherapy in patients with acute myocardial infarction, although guidelines recommend the same preventive approach in both women and men. This study builds upon previous research by examining temporal trends in prescribing patterns of secondary prevention medications using contemporary, long-term data from Switzerland, with particular focus on sex-related disparities.</p><p><strong>Methods: </strong>Acute myocardial infarction patients enrolled in the AMIS (Acute Myocardial Infarction in Switzerland) Plus project between 2003 and 2022 were included. For this retrospective analysis, optimal medical therapy was defined as the combination of all five guideline-recommended medications at discharge: aspirin; P2Y12 inhibitor; lipid-lowering drug; beta-blocker; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Uni- and multivariable logistic regression analyses were performed.</p><p><strong>Results: </strong>Among 34,612 patients (75% men, n=25,913), women were older and had more comorbidities but were less frequently prescribed optimal medical therapy than men (51% vs 60%) across all age groups (all p <0.001), with the greatest gap occurring in patients <50 years of age. A marked increase in optimal medical therapy prescription (36% to 60%) was detected irrespective of age and sex, mainly due to greater prescription of dual antiplatelet therapy (71% to 91%) and lipid-lowering drugs (69% to 93%). The sex-related gap in optimal medical therapy prescription disfavouring women showed a fluctuating trend (0.7-14%) whereas there was a progressive and sustained reduction regarding the combination of dual antiplatelet therapy plus lipid-lowering drug, from 18% to 10% at the beginning and the end of the observation period, respectively. Multivariable analysis showed greater frequency of optimal medical therapy prescription in patients with STEMI (OR: 1.65, 95% CI: 1.57-1.73) and those treated with PCI (OR: 4.85, 95% CI: 4.49-5.24), whereas lower prescription frequencies were observed among female patients (OR: 0.90, 95% CI: 0.85-0.95) and older individuals (OR per additional year: 0.99, 95% CI: 0.98-0.99).</p><p><strong>Conclusions: </strong>Although optimal medical therapy prescription increased gradually over time among both women and men, concerning sex disparities disfavouring women, particularly young women, remained. Targeted programmes to reduce sex-related differences in secondary prevention care are warranted.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4681"},"PeriodicalIF":1.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building Advanced Practice Nursing in Swiss community care: key messages from a national symposium.","authors":"Joanie Pellet, Cedric Mabire, Franziska Zúñiga, Isabelle Peytreman-Bridevaux, Manuela Eicher","doi":"10.57187/5381","DOIUrl":"https://doi.org/10.57187/5381","url":null,"abstract":"<p><p>Advanced Practice Nursing is emerging as one of Switzerland's most promising levers to keep community care accessible and coordinated despite physician shortages, rising multimorbidity and an ageing population. While international evidence supports the contribution of Advanced Practice Nurses to access, continuity and quality of care, their integration within the Swiss healthcare system remains heterogeneous. In this context, the symposium \"Advanced Practice Nursing: Building future care by integrating Advanced Practice Nursing into community settings\" was held in December 2025 and organised by Unisanté and the Institute of Higher Education and Research in Healthcare (IUFRS) of Lausanne University, in partnership with Lausanne University Hospital (CHUV), the Institute of Nursing Science (Institut für Pflegewissenschaft) of the University of Basel, the University of Applied Sciences and Arts Western Switzerland (HES-SO), the Swiss School of Public Health (SSPH+) and the Swiss Academy of Medical Sciences (SAMW/ASSM).</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5381"},"PeriodicalIF":1.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementum 304: Abstracts of the annual meeting of the Swiss Society of Gastroenterology, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates (Interlaken, Switzerland, September 17-18, 2026).","authors":"Swiss Society Of Gastroenterology, Swiss Association For The Study Of The Liver, Swiss Society Of Endoscopy Nurses And Associates","doi":"10.57187/5757","DOIUrl":"https://doi.org/10.57187/5757","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"304"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}